Piper Sandler analyst David Amsellem reiterated a Buy rating on Xeris Pharmaceuticals (XERS – Research Report) today and set a price target of $5.00. The company’s shares closed yesterday at $2.73.
Amsellem covers the Healthcare sector, focusing on stocks such as Collegium Pharmaceutical, Supernus Pharmaceuticals, and Alkermes. According to TipRanks, Amsellem has an average return of -2.6% and a 42.95% success rate on recommended stocks.
Currently, the analyst consensus on Xeris Pharmaceuticals is a Strong Buy with an average price target of $5.33, representing a 95.24% upside. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $6.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Based on Xeris Pharmaceuticals’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $33.14 million and a GAAP net loss of $12.93 million. In comparison, last year the company earned a revenue of $22.07 million and had a GAAP net loss of $33.71 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Xeris Pharmaceuticals, Inc.is a pharmaceutical company, which develops and commercializes ready-to-use, liquid-stable injectables. It offers XeriSol™ and XeriJect™ formulation technologies. The company was founded by Steven Prestrelski and John Kinzell in 2005 and is headquartered in Austin, TX.
Read More on XERS:
